Cancer Causes & Control

, Volume 23, Issue 4, pp 547–553 | Cite as

Sleep duration and endometrial cancer risk

  • Susan R. Sturgeon
  • Nicole Luisi
  • Raji Balasubramanian
  • Katherine W. Reeves
Original paper



Recent data indicate that night shift work is associated with increased endometrial cancer risk, perhaps through a pathway involving lower melatonin production. Melatonin is an antiestrogenic hormone, with production in a circadian pattern that is dependent on presence of dark at night. Sleep duration is positively associated with melatonin production and may be an indicator of melatonin levels in epidemiologic studies.


We evaluated associations between self-reported sleep duration and endometrial cancer risk using publicly available prospective data on 48,725 participants in the Women’s Health Initiative Observational Study, among whom 452 adjudicated incident cases of endometrial cancer were diagnosed over approximately 7.5 years of follow-up. Sleep duration was self-reported at baseline. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for endometrial cancer risk with adjustment for potential confounders.


Most women reported sleeping ≤6 (33.3%) or 7 (38.5%) h each night; fewer reported sleeping 8 (23.4%) or ≥9 (4.8%) h each night. In adjusted analyses, there was an indication of reduced risk associated with longer sleep duration, though no statistically significant association was observed. Women who slept ≥9 h had a nonsignificant reduced risk of endometrial cancer compared with women who slept ≤6 h (HR = 0.87; 95% CI = 0.51–1.46).


We found weak evidence of an association between sleep duration and endometrial cancer risk. Self-reported sleep duration may not adequately represent melatonin levels, thus further studies utilizing urinary melatonin levels are necessary to establish the mechanism by which night shift work increases endometrial cancer risk.


Endometrial cancer incidence Sleep duration Cohort study 


  1. 1.
    American Cancer Society (2010) Cancer facts and figures 2010. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Viswanathan AN, Hankinson SE, Schernhammer ES (2007) Night shift work and the risk of endometrial cancer. Cancer Res 67:10618–10622PubMedCrossRefGoogle Scholar
  3. 3.
    Straif K, Baan R, Grosse Y et al (2007) Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 8:1065–1066PubMedCrossRefGoogle Scholar
  4. 4.
    Blask DE (2009) Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 73:25–64Google Scholar
  5. 5.
    Viswanathan AN, Schernhammer ES (2008) Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett 281:1–7PubMedCrossRefGoogle Scholar
  6. 6.
    Schernhammer ES, Berrino F, Krogh V et al (2010) Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 19:729–737PubMedCrossRefGoogle Scholar
  7. 7.
    Wang XS, Armstrong ME, Cairns BJ, Key TJ, Travis RC (2011) Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond) 61:78–89CrossRefGoogle Scholar
  8. 8.
    Wu AH, Wang R, Koh WP, Stanczyk FZ, Lee HP, Yu MC (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29:1244–1248PubMedCrossRefGoogle Scholar
  9. 9.
    Verkasalo PK, Lillberg K, Stevens RG et al (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65:9595–9600PubMedCrossRefGoogle Scholar
  10. 10.
    Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66:5521–5525PubMedCrossRefGoogle Scholar
  11. 11.
    Kakizaki M, Kuriyama S, Sone T et al (2008) Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99:1502–1505PubMedCrossRefGoogle Scholar
  12. 12.
    Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 19:61–109CrossRefGoogle Scholar
  13. 13.
    Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 13:S122–S128PubMedCrossRefGoogle Scholar
  14. 14.
    Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA (2005) Validation of the Women’s Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. Psychosom Med 67:98–104PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Susan R. Sturgeon
    • 1
  • Nicole Luisi
    • 1
  • Raji Balasubramanian
    • 1
  • Katherine W. Reeves
    • 1
  1. 1.Division of Biostatistics and Epidemiology, School of Public Health and Health SciencesUniversity of Massachusetts AmherstAmherstUSA

Personalised recommendations